Drugs / S095033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05312372 | May 2025 → Jun 2026 | esophageal squamous cell carcinoma | Servier | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S095033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05312372 ↗ |
| Action | Inhibit | “S095033 (MAT2A Inhibitor)” NCT05312372 ↗ |
| Target | MAT2A | “S095033 (MAT2A Inhibitor)” NCT05312372 ↗ |